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Abstract. Early-onset cardiovascular and renal diseases have 
a strong genetic component. In the present study, exome-wide 
association studies (EWASs) were performed to identify 
genetic variants that confer susceptibility to early-onset 
myocardial infarction (MI), hypertension, or chronic kidney 
disease (cKd) in Japanese individuals. A total of 8,093 
individuals aged ≤65 years was enrolled in the study. The 
EWASs for MI, hypertension, and cKd were performed in 
6,926 subjects (1,152 cases, 5,774 controls), 8,080 subjects 
(3,444 cases, 4,636 controls), and 2,556 subjects (1,051 cases, 
1,505 controls), respectively. Genotyping of single nucleotide 
polymorphisms (SNPs) was performed with Illumina Human 
Exome‑12 DNA Analysis BeadChip or Infinium Exome‑24 
Beadchip arrays. The associations of allele frequencies for 
31,245, 31,276, or 31,514 SNPs that passed quality control to 
MI, hypertension, and cKd, respectively, was examined with 
Fisher's exact test. Bonferroni's correction for statistical signif-
icance of association was applied to compensate for multiple 
comparisons of genotypes with MI, hypertension, or cKd. The 
EWASs of allele frequencies revealed that 25, 11, and 11 SNPs 
were significantly associated with MI (P<1.60x10-6), hyper-
tension (P<1.60x10-6), or CKD (P<1.59x10-6), respectively. 
Multivariable logistic regression analysis with adjustment 
for covariates showed that all 25, 11, and 11 SNPs were 
significantly associated with MI (P<0.0005), hypertension 
(P<0.0011), or CKD (P<0.0011), respectively. On examination 
of the results from previous genome-wide association studies 
and linkage disequilibrium of the identified SNPs, 11 loci 
(TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, OR52E4, 
TCHP‑GIT2, CCDC63, 12q24.1, OAS3, PLCB2‑VPS33B, 
GOSR2, ZNF77), six loci (MOB3C‑TMOD4, COL6A3, 
COL6A5, CXCL8‑MARCH1, NFKBIL1‑6p21.3‑NCR3, 
PLCB2‑VPS33B), and seven loci (MOB3C‑TMOD4, 
COL6A3, COL6A5, ADGRL3‑CXCL8‑MARCH1, MUC17, 
PLCB2‑VPS33B, ZNF77) were identified as novel loci 
significantly associated with MI, hypertension, and cKd, 
respectively. Furthermore, six genes (TMOD4, COL6A3, 
CXCL8, MARCH1, PLCB2, VPS33B) were significantly asso-
ciated with MI, hypertension and cKd; two genes (ADGRL3, 
ZNF77) with MI and cKd; and two genes (COL6A5, 
MOB3C) with hypertension and cKd. Therefore, 13 novel loci 
(MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, 
OR52E4,  TCHP‑ GIT2,  CCDC63,  12q24.1,  OAS3, 
PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, MUC17) 
were identified that confer susceptibility to early‑onset MI, 
hypertension, or cKd. The determination of genotypes for the 
SNPs at these loci may provide informative for assessment of 
the genetic risk for MI, hypertension, or cKd.
Introduction
coronary artery disease (cAd) and myocardial infarc-
tion (MI) are serious clinical conditions that remain the 
leading causes of mortality in the United States (1). disease 
prevention is an important strategy for reducing the overall 
burden of these conditions, with the identification of 
biomarkers for disease risk being key for risk prediction 
and for potential intervention to reduce the chance of future 
coronary events.
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In addition to conventional risk factors for cAd and MI, 
including hypertension, diabetes mellitus, and dyslipidemia, 
the importance of genetic factors has been highlighted (2). 
The heritability of cAd has been estimated to be 40-60% 
on the basis of family and twin studies (2,3). Genome-wide 
association studies (GWASs) in European-ancestry popula-
tions (4-10), African Americans (11), or Han chinese (12,13) 
have identified various genes and loci that confer susceptibility 
to cAd or MI. A meta-analysis of GWASs for cAd among 
European-ancestry populations, which included low-frequency 
variants, identified 202 independent genetic variants at 129 
loci with a false discovery rate of <5% (14). These genetic 
variants together account for ~28% of the heritability of cAd, 
showing that genetic susceptibility to this condition is largely 
determined by common variants with small effect sizes (2,14). 
A more recent meta-analysis for cAd in European-ancestry 
populations identified 304 independent genetic variants with 
a false discovery rate of <5%, with these variants explaining 
21.2% of cAd heritability (15). Although several single nucleo-
tide polymorphisms (SNPs) have been found to be significantly 
associated with MI in Japanese individuals (16,17), genetic 
variants that contribute to susceptibility to MI in the Japanese 
population remain to be fully elucidated.
Hypertension is a complex multifactorial disorder that 
results from an interaction between genetic background and 
both lifestyle and environmental factors (18). The heritability 
of hypertension has been estimated to be 84% and that of 
systolic blood pressure (BP) and diastolic BP has been esti-
mated to be 53 and 49%, respectively (19). As hypertension 
is a major risk factor for cAd and stroke (20), personalized 
prevention of hypertension is an important public health goal.
GWASs have implicated various loci and genes as influ-
encing BP or conferring susceptibility to hypertension in 
populations in Europe (6,21-24) and African (25,26) and in 
individuals from East Asia (27). A trans-ancestry GWAS in 
individuals of European and East or South Asian ancestry 
identified 12 loci associated with BP (28). A previous 
trans-ancestry meta-analysis in individuals of European and 
South Asian ancestry identified 30 susceptibility loci for BP 
or hypertension (29). Although an SNP in ADD2 was shown 
to be a susceptibility locus for hypertension in Japanese indi-
viduals (30), genetic variants that confer susceptibility to this 
condition in Japanese individuals await definitive identification.
chronic kidney disease (cKd) is also a global public health 
problem, with affected individuals being at increased risk for 
end-stage renal disease (ESRd), cardiovascular disease and 
premature death (31,32). The identification of biomarkers for 
cKd risk is important to prevent progression to ESRd and to 
reduce the chance of future cardiovascular adverse events (33). 
In addition to conventional risk factors for cKd, including 
diabetes mellitus and hypertension (34), studies have shown 
the importance of genetic factors in renal function and in 
the development of cKd (35). The heritability of glomerular 
filtration rate for creatinine clearance has been estimated to be 
52% (36).
GWASs have implicated several genes and loci in renal 
function or predisposition to cKd or ESRd in popula-
tions of European (37-42) or African (43) ancestry, and in 
renal function-related traits in East Asian populations (44). 
A meta-analysis of GWASs in European populations 
identified 53 loci that were significantly associated with esti-
mated glomerular filtration rate (eGFR) (45). Although several 
SNPs have been shown to be associated with renal function in 
East Asian populations (44), genetic variants that contribute to 
predisposition to cKd in the Japanese population remain to 
be fully elucidated.
A previous study of monozygotic and dizygotic twins 
found that cAd-associated mortality rate at younger ages 
was significantly influenced by genetic factors in men and 
women, whereas the genetic effect was less pronounced at 
older ages (46). A family history of MI is also more apparent 
in individuals with early-onset MI compared with those 
with late-onset MI, suggestive of increased heritability in 
the former individuals (47,48). Similar to early-onset MI, 
early-onset forms of hypertension (49) and cKd (35) have 
been found to have a strong genetic component. As the genetic 
contribution may be higher in early-onset than in late-onset 
MI, hypertension and cKd, the statistical power of genetic 
association studies may be increased by focusing on subjects 
with early-onset disease (2,35,49).
In the present study, exome-wide association studies 
(EWASs) for MI, hypertension, and cKd were performed 
with the use of human exome array-based genotyping methods 
in order to identify genetic variants that confer susceptibility 
to these conditions in Japanese individuals. To increase the 
statistical power of the EWASs, subjects with early-onset 
disease were examined.
Materials and methods
Study subjects. In our previous EWASs, the median (mean) 
ages of subjects with MI, hypertension, and cKd were 67 
(67.0), 68 (67.2), and 70 (69.9) years, respectively (50-52). 
Therefore patients with an age of ≤65 years were defined 
as individuals with early-onset forms of these conditions in 
the present study. A total of 8,093 Japanese individuals aged 
≤65 years (subjects with MI, hypertension, or CKD and corre-
sponding controls) was enrolled in the present study. In the 
EWASs for MI, hypertension, and cKd, 6,926 individuals 
(1,152 subjects with MI, 5,774 controls), 8,080 individuals 
(3,444 subjects with hypertension, 4,636 controls), and 2,556 
individuals (1,051 subjects with cKd, 1,505 controls) were 
examined, respectively. The individuals were recruited as those 
who visited outpatient clinics or were admitted to participating 
hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; 
Gifu Prefectural General Medical center, Gifu; Japanese 
Red cross Nagoya First Hospital, Nagoya, Japan; Northern 
Mie Medical center Inabe General Hospital, Inabe, Japan; 
and Hirosaki University Hospital and Hirosaki Stroke and 
Rehabilitation center, Hirosaki, Japan) due to the presence of 
various symptoms or for an annual health checkup between 
2002 and 2014, or who were community-dwelling individuals 
recruited to a population-based cohort study in Inabe between 
2010 and 2014 (53).
For the MI study, the diagnosis of MI was based on 
typical electrocardiographic changes and on increases in 
the serum activity of creatine kinase (MB isozyme) and in 
the serum concentration of troponin T. The diagnosis was 
confirmed by identification of the responsible stenosis in any 
of the major coronary arteries or in the left main trunk by 
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coronary angiography. The control individuals had no history 
of MI, cAd, aortic aneurysm, or peripheral artery disease; of 
ischemic or hemorrhagic stroke; or of other atherosclerotic, 
thrombotic, embolic, or hemorrhagic disorders. Although 
certain control individuals had conventional risk factors for 
MI, including hypertension, diabetes mellitus, dyslipidemia, 
and cKd, they did not have cardiovascular complications.
In the hypertension study, the subjects with hypertension 
either had a systolic BP of ≥140 mmHg or diastolic BP of 
≥90 mmHg (or both), or had taken antihypertensive medica-
tion. Individuals with severe valvular heart disease, congenital 
malformations of the heart or vessels, renal or endocrinologic 
diseases that cause secondary hypertension, or drug-induced 
hypertension were excluded from the study. The control 
individuals had a systolic BP of <140 mmHg and diastolic 
BP of <90 mmHg and no history of hypertension or of taking 
antihypertensive medication. BP was measured at least twice 
by a skilled physician or nurse, with subjects having first rested 
in the sitting position for >5 min.
For the CKD study, glomerular filtration rate was estimated 
with the use of the simplified prediction equation derived from 
a modified version of that described in the Modification of Diet 
in Renal disease Study, as suggested by the Japanese Society 
of Nephrology (54): eGFR (ml min-1 1.73 m-2) = 194 x [age 
(years)]-0.287 x [serum creatinine (mg/dl)]-1.094 x [0.739 if female]. 
The National Kidney Foundation-Kidney disease Outcomes 
Quality Initiative guidelines recommend a diagnosis of cKd 
if eGFR is <60 ml min-1 1.73 m-2 (55). Nonlinear relations 
between eGFR and the risk of adverse events, including 
mortality, cardiovascular episodes, and hospitalization, have 
been demonstrated, with an increased risk being associated 
with an eGFR of <60 ml min-1 1.73 m-2 and the risk markedly 
increasing further when values fall <45 ml min-1 1.73 m-2 (56). 
Therefore, the criterion of an eGFR of <60 ml min-1 1.73 m-2 
was used for the diagnosis of cKd. The control individuals 
for the CKD study had an eGFR of ≥90 ml min-1 1.73 m-2 and 
had no functional or structural abnormalities of the kidneys 
or a history of renal disease. Although certain control indi-
viduals had hypertension, diabetes mellitus, dyslipidemia, or 
hyperuricemia, they had no renal complications.
A total of 785 subjects with both MI and hypertension 
and 3,946 controls overlapped between the corresponding 
studies, as did 324 subjects with both MI and cKd and 1,127 
controls, and 750 subjects with both hypertension and cKd 
and 955 controls.
EWASs. Venous blood (5 or 7 ml) was collected into tubes 
containing 50 mmol/l ethylenediaminetetraacetic acid (diso-
dium salt), peripheral blood leukocytes were isolated, and 
genomic dNA was extracted from these cells with the use of 
a Genomix dNA extraction kit (Talent Srl, Trieste, Italy) or 
SMITEST EX-R&d kit (Medical & Biological Laboratories, 
co., Ltd., Nagoya, Japan). The EWASs for MI (1,152 cases, 
5,774 controls), hypertension (3,444 cases, 4,636 controls), 
and cKd (1,051 cases, 1,505 controls) were performed with 
the use of a Human Exome-12 v1.2 dNA Analysis Beadchip 
or Infinium Exome‑24 v1.0 BeadChip (Illumina, San Diego, 
cA, USA). These exome arrays include putative functional 
exonic variants selected from ~12,000 individual exome 
and whole-genome sequences. The exonic content consists 
of ~244,000 SNPs from European, African, chinese, and 
Hispanic individuals (57). SNPs contained in only one of the 
exome arrays (~2.6% of all SNPs) were excluded from analysis. 
Quality control was performed (58) as follows: i) Genotyping 
data with a call rate of <97% were discarded, with the mean 
call rate for the remaining data being 99.9%; ii) sex specifica-
tion was checked for each sample, and those for which sex 
phenotype in the clinical records was inconsistent with genetic 
sex chromosomes were discarded; iii) duplicate samples and 
cryptic relatedness were assessed by calculation of identity 
by descent; all pairs of dNA samples showing an identity 
by descent of >0.1875 were inspected and one sample from 
each pair was excluded; iv) the frequency of heterozygosity 
for SNPs was calculated for all samples, and those with low 
or high heterozygosity (>3 standard deviations from the mean) 
were discarded; v) SNPs in sex chromosomes or mitochondrial 
dNA were excluded from the analysis, as were nonpolymor-
phic SNPs or SNPs with a minor allele frequency of <1.0%; 
vi) SNPs with genotype distributions deviating significantly 
(P<0.01) from Hardy‑Weinberg equilibrium in control indi-
viduals were discarded; vii) genotype data were examined for 
population stratification by principal components analysis (59), 
and population outliers were excluded from the analysis. A 
total of 31,245, 31,276, or 31,514 SNPs passed quality control 
for the EWASs of MI, hypertension, and cKd, respectively, 
and these SNPs were subjected to analyses.
Statistical analysis. For analysis of the characteristics of the 
study subjects, quantitative data were compared between 
subjects with MI, hypertension, or cKd and corresponding 
controls with an unpaired t-test. categorical data were 
compared between the two groups with Pearson's χ2 test. Allele 
frequencies were estimated by the gene counting method, 
and Fisher's exact test was applied to identify departure from 
Hardy-Weinberg equilibrium. In the EWASs, the relation of 
allele frequencies of each SNP to MI, hypertension, or cKd was 
examined with Fisher's exact test. To compensate for multiple 
comparisons of genotypes with MI, hypertension, or cKd, 
Bonferroni's correction was applied for statistical significance 
of association. As 31,245, 31,276, and 31,514 SNPs that passed 
quality control were examined in the EWASs for MI, hyper-
tension, and CKD, respectively, P<1.60x10-6 (0.05/31,245 and 
31,276) for MI and hypertension or P<1.59x10-6 (0.05/31,514) 
for CKD was considered statistically significant. The inflation 
factor (λ) was 0.95 for MI, 1.03 for hypertension, and 1.07 for 
cKd. Multivariable logistic regression analysis was performed 
with MI as a dependent variable and independent variables 
included age, sex (0, woman; 1, man), the prevalence of hyper-
tension, diabetes mellitus, and dyslipidemia (0, no history of 
these conditions; 1, positive history), and the genotype of each 
SNP. Similar analysis was performed with hypertension as a 
dependent variable and independent variables of age, sex, and 
the genotype of each SNP; and with cKd as a dependent vari-
able and independent variables of age, sex, the prevalence of 
hypertension and diabetes mellitus, and the genotype of each 
SNP. The genotypes of the SNPs were assessed according 
to dominant [0, AA; 1, AB + BB (A, major allele; B, minor 
allele)], recessive (0, AA + AB; 1, BB), and additive genetic 
models, and the P‑value, odds ratio, and 95% confidence 
interval were calculated. Additive models comprised additive 
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1 (0, AA; 1, AB; 0, BB) and additive 2 (0, AA; 0, AB; 1, BB) 
scenarios, which were analyzed simultaneously with a single 
statistical model. The association between the genotypes 
of SNPs and intermediate phenotypes of MI was examined 
with Pearson's χ2 test. The association between genotypes of 
SNPs and systolic or diastolic BP, the serum concentration 
of creatinine, or eGFR was examined by one-way analysis of 
variance (ANOVA). Bonferroni's correction was also applied 
to other statistical analysis as indicated. Statistical tests were 
performed with JMP Genomics version 9.0 software (SAS 
Institute, cary, Nc, USA).
Results
Characteristics of subjects. The characteristics of the 6,926 
subjects enrolled in the MI study are shown in Table I. The 
age, the frequency of men, and the prevalence of obesity, 
hypertension, diabetes mellitus, dyslipidemia, cKd, and 
hyperuricemia, in addition to body mass index (BMI), systolic 
and diastolic BP, fasting plasma glucose (FPG) level, blood 
glycosylated hemoglobin (hemoglobin A1c) content, and the 
serum concentrations of triglycerides, creatinine, and uric 
acid were higher, whereas the serum concentration of high 
density lipoprotein (HdL)-cholesterol and eGFR were lower, 
in subjects with MI than in controls.
The characteristics of the 8,080 subjects enrolled in 
the hypertension study are shown in Table II. The age, the 
frequency of men, and the prevalence of obesity, diabetes 
mellitus, dyslipidemia, cKd, and hyperuricemia, in addi-
tion to the BMI, FPG level, blood hemoglobin A1c content, 
and the serum concentrations of triglycerides, creatinine, 
and uric acid were higher, whereas the serum concentration 
of HdL-cholesterol and eGFR were lower, in subjects with 
hypertension than in controls.
The characteristics of the 2,556 subjects enrolled in the cKd 
study are shown in Table III. The age, the frequency of men, and 
the prevalence of obesity, hypertension, diabetes mellitus, dyslip-
idemia, and hyperuricemia, in addition to the BMI, systolic and 
diastolic BP, FPG level, blood hemoglobin A1c content, and the 
serum concentrations of triglycerides and uric acid were higher, 
whereas the serum concentration of HdL-cholesterol was lower, 
in subjects with cKd than in controls.
Table I. characteristics of subjects with MI and control individuals.
characteristic control Myocardial infarction P-value
Subjects (n) 5,774 1,152 
Age (years) 50.6±10.2 55.6±7.4 <0.0001
Sex (men/women, %) 52.1/47.9 85.4/14.6 <0.0001
Smoking (%) 42.5 46.7 0.0105
Obesity (%) 31.0 42.7 <0.0001
Body mass index (kg/m2) 23.2±3.5 24.6±3.5 <0.0001
Hypertension (%) 31.7 68.9 <0.0001
Systolic BP (mmHg) 121±18 139±26 <0.0001
Diastolic BP (mmHg) 75±13 78±16 <0.0001
Diabetes mellitus (%) 12.7 61.3 <0.0001
Fasting plasma glucose (mmol/l) 5.66±1.78 7.66±3.39 <0.0001
Blood hemoglobin A1c (%) 5.72±0.96 6.88±1.70 <0.0001
Dyslipidemia (%) 56.9 84.9 <0.0001
Serum triglycerides (mmol/l) 1.32±0.98 1.77±1.25 <0.0001
Serum HDL‑cholesterol (mmol/l) 1.65±0.45 1.17±0.34 <0.0001
Serum LdL-cholesterol (mmol/l) 3.18±0.83 3.15±0.98 0.8593
Chronic kidney disease (%) 10.3 29.1 <0.0001
Serum creatinine (µmol/l) 69.8±61.0 91.9±98.1 <0.0001
eGFR (ml min-1 1.73 m-2) 78.7±17.1 71.2±27.8 <0.0001
Hyperuricemia (%) 15.2 25.6 <0.0001
Serum uric acid (µmol/l) 321±89 356±105 <0.0001
Quantitative data are presented as the mean ± standard deviation and were compared between subjects with MI and controls using the unpaired 
t-test. categorical data were compared between the two groups with Pearson's χ2 test. Based on Bonferroni's correction, P<0.0025 (0.05/20) 
was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m2; hypertension as a systolic BP of ≥140 mmHg, 
diastolic BP of ≥90 mmHg, or the taking of anti‑hypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, 
blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride concentration of 
≥1.65 mmol/l, serum HDL‑cholesterol <1.04 mmol/l, serum LDL‑cholesterol ≥3.64 mmol/l, or the taking of anti‑dyslipidemic medication; 
chronic kidney disease as an eGFR of <60 ml min-1 1.73 m-2; and hyperuricemia as a serum uric acid concentration of >416 µmol/l or the taking 
of uric acid-lowering medication. MI, myocardial infarction; BP, blood pressure; HdL, high density lipoprotein; LdL, low density lipoprotein; 
eGFR, estimated glomerular filtration rate.
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EWASs for MI, hypertension, and CKD. The association 
between allele frequencies for the 31,245, 31,276, and 31,514 
SNPs that passed quality control to MI, hypertension, and 
cKd, respectively, were examined using Fisher's exact test. 
Following Bonferroni's correction, 25 and 11 SNPs were 
significantly (P<1.60x10-6) associated with MI (Table IV) 
or hypertension (Table V), respectively, and 11 SNPs were 
significantly (P<1.59x10-6) associated with cKd (Table VI).
Multivariable logistic regression analysis of the association 
between SNPs and MI, hypertension, or CKD. The association 
of the 25 SNPs identified in the EWAS for MI with this condi-
tion was further examined by multivariable logistic regression 
analysis with adjustment for age, sex, and the prevalence of 
hypertension, diabetes mellitus, and dyslipidemia (Table VII). 
All 25 SNPs were significantly [P<0.0005 (0.05/100) in at least 
one genetic model] associated with MI. The association between 
the 11 SNPs identified in the EWAS for hypertension and this 
condition was examined by multivariable logistic regression 
analysis with adjustment for age and sex (Table VIII). All 11 
SNPs were significantly [P<0.0011 (0.05/44)] associated with 
hypertension. The association between the 11 SNPs identified 
by the EWAS for cKd and this condition was also examined 
by multivariable logistic regression analysis with adjustment 
for age, sex, and the prevalence of hypertension and diabetes 
mellitus (Table IX). All 11 SNPs were significantly [P<0.0011 
(0.05/44)] associated with cKd.
Association between SNPs associated with MI and interme‑
diate phenotypes. The present study examined the associations 
between the 25 SNPs associated with MI and intermediate 
phenotypes of this condition, including hypertension, diabetes 
mellitus, hypertriglyceridemia, hypo-HdL-cholesterolemia, 
hyper-low density lipoprotein (LdL)-cholesterolemia, cKd, 
obesity, and hyperuricemia, using Pearson's χ2 test. The SNPs 
rs200787930 of PLCB2, rs188378669 of CXCL8, rs61734696 
of MARCH1, rs199921354 of VPS33B, rs115287176 of 
TMOD4, rs146092501 of COL6A3, rs146879198 of ZNF77, 
and rs192210727 of ADGRL3 were significantly [P<0.0003 
(0.05/200)] associated with hypo-HdL-cholesterolemia, 
hyper-LdL-cholesterolemia, and cKd, with rs61734696 
also being associated with hypertension. The SNPs rs671 
of ALDH2, rs11066015 of ACAD10, and rs11066280 and 
rs2074356 of HECTD4 were significantly associated with 
Table II. characteristics of subjects with hypertension and control individuals.
characteristic control Hypertension P-value
Subjects (n) 4636 3444 
Age (years) 49.2±10.3 55.8±7.6 <0.0001
Sex (men/women, %) 52.0/48.0 67.8/32.2 <0.0001
Smoking (%) 41.7 42.9 0.2829
Obesity (%) 24.3 44.4 <0.0001
Body mass index (kg/m2) 22.6±3.3 24.5±3.7 <0.0001
Systolic BP (mmHg) 114±12 144±24 <0.0001
Diastolic BP (mmHg) 70±10 85±14 <0.0001
Diabetes mellitus (%) 11.1 39.5 <0.0001
Fasting plasma glucose (mmol/l) 5.61±1.78 6.72±2.83 <0.0001
Blood hemoglobin A1c (%) 5.71±0.96 6.30±1.48 <0.0001
Dyslipidemia (%) 51.3 75.5 <0.0001
Serum triglycerides (mmol/l) 1.25±0.98 1.69±1.19 <0.0001
Serum HDL‑cholesterol (mmol/l) 1.63±0.46 1.41±0.45 <0.0001
Serum LdL-cholesterol (mmol/l) 3.15±0.85 3.15±0.88 0.9206
Chronic kidney disease (%) 8.1 24.0 <0.0001
Serum creatinine (µmol/l) 65.4±23.9 89.3±117.6 <0.0001
eGFR (ml min-1 1.73 m-2) 80.4±18.8 72.5±21.3 <0.0001
Hyperuricemia (%) 11.3 25.2 <0.0001
Serum uric acid (µmol/l) 311±86 349±99 <0.0001
Quantitative data are presented as the mean ± standard deviation and were compared between subjects with hypertension and controls with the 
unpaired t-test. categorical data were compared between the two groups with Pearson's χ2 test. Based on Bonferroni's correction, P<0.0026 
(0.05/19) was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m2; hypertension as a systolic BP of 
≥140 mmHg, diastolic BP of ≥90 mmHg, or the taking of antihypertensive medication; diabetes mellitus as a fasting plasma glucose level 
of ≥6.93 mmol/l, blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride 
concentration of ≥1.65 mmol/l, serum HDL‑cholesterol <1.04 mmol/l, serum LDL‑cholesterol ≥3.64 mmol/l, or the taking of anti‑dyslipidemic 
medication; chronic kidney disease as an eGFR of <60 ml min-1 1.73 m-2; and hyperuricemia as a serum uric acid concentration of >416 µmol/l 
or the taking of uric acid-lowering medication. BP, blood pressure; HdL, high density lipoprotein; LdL, low density lipoprotein; eGFR, 
estimated glomerular filtration rate.
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hypo-HdL-cholesterolemia, hyper-LdL-cholesterolemia, 
and hyperuricemia. The SNPs rs3782886 of BRAP and 
rs12229654 at 12q24.1 were significantly associated with 
hypo-HdL-cholesterolemia and hyperuricemia. The 
SNP rs11823828 of OR52E4 was significantly associ-
ated with diabetes mellitus, rs12231744 of NAA25 with 
hypo-HdL-cholesterolemia, rs7969300 of ATXN2 with hyper-
triglyceridemia, and rs10774610 and rs10849915 of CCDC63 
with hyperuricemia (Table X).
Association between SNPs associated with hypertension 
and systolic or diastolic BP. The present study examined the 
associations between genotypes for the 11 SNPs associated 
with hypertension and systolic or diastolic BP by one-way 
ANOVA (Table XI). All 11 SNPs were significantly [P<0.0023 
(0.05/22)] associated with systolic BP, whereas only rs2071593 
of NFKBIL1 was associated with diastolic BP.
Association between SNPs associated with CKD and the 
serum concentration of creatinine or eGFR. The present 
study examined the associations between the 11 SNPs asso-
ciated with cKd and the serum concentration of creatinine 
or eGFR by one-way ANOVA (Table XII). All 11 SNPs were 
significantly [P<0.0023 (0.05/22)] associated with eGFR, 
however, none were associated with the serum concentration 
of creatinine.
Linkage disequilibrium analyses. The linkage disequilibrium 
(Ld) among SNPs associated with MI, hypertension, or cKd 
was examined. For the MI study, rs192210727 of ADGRL3, 
rs188378669 of CXCL8, and rs61734696 of MARCH1 were 
in LD [square of the correlation coefficient (r2), 0.907-0.972]. 
Two SNPs (rs2596548, rs2523644) at chromosome 6p21.3 
were also in Ld (r2=0.624). Ld plots of the 13 SNPs located at 
chromosome 12q24.11 to 12q24.13 are shown in Fig. 1. There 
was significant LD between rs74416240 of TCHP and rs925368 
of GIT2 (r2=0.937); between rs10849915 and rs10774610 
of CCDC63 (r2=0.992); and among rs3782886 of BRAP, 
rs11066015 of ACAD10, rs671 of ALDH2, and rs2074356 and 
rs11066280 of HECTD4 (r2=0.814‑0.994). A significant LD 
(r2=0.994) was also apparent between rs200787930 of PLCB2 
and rs199921354 of VPS33B.
For the hypertension study, there was significant Ld 
between rs139537100 of MOB3C and rs115287176 of TMOD4 
Table III. characteristics of subjects with cKd and control individuals.
characteristic control cKd P-value
Subjects (n) 1,505 1,051 
Age (years) 48.5±10.3 57.7±6.5 <0.0001
Sex (men/women, %) 53.8/46.2 68.9/31.1 <0.0001
Smoking (%) 43.2 37.3 0.0028
Obesity (%) 29.1 38.9 <0.0001
Body mass index (kg/m2) 23.1±3.8 24.1±3.5 <0.0001
Hypertension (%) 36.5 71.4 <0.0001
Systolic BP (mmHg) 126±23 141±29 <0.0001
Diastolic BP (mmHg) 76±14 80±16 <0.0001
Diabetes mellitus (%) 24.8 45.2 <0.0001
Fasting plasma glucose (mmol/l) 6.27±2.72 6.88±3.16 <0.0001
Blood hemoglobin A1c (%) 6.08±1.51 6.42±1.51 <0.0001
Dyslipidemia (%) 56.4 75.3 <0.0001
Serum triglycerides (mmol/l) 1.35±1.21 1.69±1.07 <0.0001
Serum HDL‑cholesterol (mmol/l) 1.56±0.47 1.38±0.48 <0.0001
Serum LdL-cholesterol (mmol/l) 3.08±0.85 3.13±0.93 0.0738
Serum creatinine (µmol/l) 51.7±9.3 150.3±198.0 <0.0001
eGFR (ml min-1 1.73 m-2) 103.0±19.1 46.9±14.6 <0.0001
Hyperuricemia (%) 8.5 40.6 <0.0001
Serum uric acid (µmol/l) 297±80 381±106 <0.0001
Quantitative data are presented as the mean ± standard deviation and were compared between subjects with cKd and controls with the unpaired 
t-test. categorical data were compared between the two groups with Pearson's χ2 test. Based on Bonferroni's correction, P<0.0026 (0.05/19) 
was considered statistically significant. Obesity was defined as a body mass index of ≥25 kg/m2; hypertension as a systolic BP of ≥140 mmHg, 
diastolic BP of ≥90 mmHg, or the taking of antihypertensive medication; diabetes mellitus as a fasting plasma glucose level of ≥6.93 mmol/l, 
blood hemoglobin A1c content of ≥6.5%, or the taking of antidiabetic medication; dyslipidemia as a serum triglyceride concentration of 
≥1.65 mmol/l, serum HDL‑cholesterol <1.04 mmol/l, serum LDL‑cholesterol ≥3.64 mmol/l, or the taking of anti‑dyslipidemic medication; 
chronic kidney disease as an eGFR of <60 ml min-1 1.73 m-2; and hyperuricemia as a serum uric acid concentration of >416 µmol/l or the 
taking of uric acid-lowering medication. cKd, chronic kidney disease; BP, blood pressure; HdL, high density lipoprotein; LdL, low density 
lipoprotein; eGFR, estimated glomerular filtration rate.
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(r2=0.984); between rs188378669 of CXCL8 and rs61734696 
of MARCH1 (r2=0.972); among rs2071593 of NFKBIL1, 
rs769177 at 6p21.3, and rs2515920 of NCR3 (r2=0.883-0.980); 
and between rs200787930 of PLCB2 and rs199921354 of 
VPS33B (r2=0.994).
For the cKd study, complete Ld (r2=1.000) was apparent 
between rs139537100 of MOB3C and rs115287176 of TMOD4, 
and between rs200787930 of PLCB2 and rs199921354 of 
VPS33B. Significant LD (r2=0.905-0.952) was also observed 
among rs192210727 of ADGRL3, rs188378669 of CXCL8, and 
rs61734696 of MARCH1.
Associations between the genes, chromosomal loci and SNPs 
identified in the present study and the phenotypes examined 
in previous GWASs. The present study examined the associa-
tion of the genes, chromosomal loci and SNPs identified in the 
present study with the phenotypes previously investigated 
by GWASs available in the Genome-Wide Repository of 
Associations Between SNPs and Phenotypes Search data-
base (https://grasp.nhlbi.nih.gov/Search.aspx) developed by 
the Information Technology and Applications center at the 
National center for Biotechnology Information (National 
Heart, Lung, and Blood Institute, National Institutes of Health, 
Bethesda, Md, USA) (60,61).
For the MI study, chromosomal region 6p21.3, ATXN2, 
BRAP, ACAD10, ALDH2, NAA25, and HECTD4 were previ-
ously shown to be associated with MI or cAd (Table XIII). 
The remaining 15 genes or loci identified in the present study 
have not been previously found to be associated with MI or 
cAd, although GOSR2 was previously found to be associ-
ated with systolic BP. For the hypertension study, none of the 
genes, chromosomal loci, or SNPs identified were found to be 
associated with systolic or diastolic BP or with hypertension in 
previous GWASs, although 6p21.3 was previously shown to be 
associated with cAd (Table XIV). For the cKd study, none 
of the genes or SNPs identified were shown to be associated 
with renal function-related traits or cKd in previous GWASs 
(Table XV).
Gene Ontology (GO) analysis of genes identified in the present 
study. The potential biological functions of the 18 genes 
(MOB3C, TMOD4, COL6A3, ADGRL3, CXCL8, MARCH1, 
OR52E4, TCHP, GIT2, CCDC63, OAS3, PLCB2, VPS33B, 
ZNF77, COL6A5, NFKBIL1, NCR3, MUC17) identified in the 
Table IV. 25 SNPs significantly (P<1.60x10-6) associated with myocardial infarction in the exome-wide association study.
  Nucleotide Amino acid     P-value
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR (allele frequency)
PLCB2 rs200787930 c/T E1106K 15 40289298 1.2 0.01 8.81x10-26
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 0.01 1.33x10-25
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 0.01 1.50x10-25
VPS33B rs199921354 c/T R80Q 15 91013841 1.2 0.01 2.07x10-25
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 0.01 9.03x10-25
COL6A3 rs146092501 c/T E1386K 2 237371861 1.2 0.02 1.27x10-24
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 0.02 1.27x10-24
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 0.07 1.12x10-20
ALDH2 rs671 G/A E504K 12 111803962 27.6 1.54 2.67x10-19
ACAD10 rs11066015 G/A  12 111730205 27.5 0.65 3.35x10-19
BRAP rs3782886 A/G  12 111672685 29.3 1.49 5.52x10-17
HECTD4 rs11066280 T/A  12 112379979 29.0 1.49 6.48x10-17
HECTD4 rs2074356 c/T  12 112207597 25.4 1.48 4.24x10-15
OR52E4 rs11823828 T/G F227L 11 5884973 36.6 1.43 1.86x10-12
 rs12229654 T/G  12 110976657 22.5 1.39 1.45x10-10
NAA25 rs12231744 c/T R876K 12 112039251 35.1 0.74 1.07x10-9
ATXN2 rs7969300 T/c N248S 12 111555908 38.8 0.76 8.46x10-9
GOSR2 rs1052586 T/c  17 46941097 48.7 0.78 1.80x10-7
TCHP rs74416240 G/A  12 109904793 13.3 1.37 2.47x10-7
GIT2 rs925368 A/G N389S 12 109953174 12.5 1.37 4.41x10-7
 rs2523644 A/G  6 31374707 8.1 1.49 4.75x10-7
OAS3 rs2072134 c/T  12 112971371 17.6 1.33 5.28x10-7
CCDC63 rs10774610 T/c  12 110902439 23.7 1.30 5.42x10-7
 rs2596548 G/T  6 31362769 5.4 1.60 6.01x10-7
CCDC63 rs10849915 T/c  12 110895818 23.6 1.28 7.71x10-7
Allele frequencies were analyzed using Fisher's exact test. aMajor allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele 
frequency; OR, odds ratio.
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present study were examined with the use of the QuickGO data-
base of Gene Ontology and GO Annotations (https://www.ebi.
ac.uk/QuickGO; European Bioinformatics Institute, European 
Molecular Biology Laboratory, Hinxton, UK) (62,63). The GO 
analysis predicted various biological functions for the 18 genes, 
including those associated with muscle contraction (TMOD4), 
cell adhesion (COL6A3, COL6A5), G protein-coupled receptor 
signaling (ADGRL3, OR52E4, PLCB2), the inflammatory 
response (CXCL8), the immune response (MARCH1, OAS3, 
NCR3), apoptosis (TCHP), GTPase activity (GIT2), protein 
transport (VPS33B), NF-κB signaling (NFKBIL1), and lectin 
receptor signaling (MUC17) (Table XVI).
Network analysis of genes identified in the present study. 
Network analysis of the 18 genes identified in the present 
study was performed to predict functional gene-gene 
interactions with the use of the GeneMANIA cytoscape 
plugin (http://apps.cytoscape.org/apps/genemania; donnelly 
centre for cellular and Biomolecular Research, University 
of Toronto, Toronto, ON, canada) (64-66) and cytoscape 
v3.4.0 software (http://www.cytoscape.org; The cytoscape 
consortium, San diego, cA, USA) (67). Three sets of 
50 genes were selected from the disGeNET database 
(http://www.disgenet.org/web/disGeNET; Integrative 
Biomedical Informatics Group, Research Programme on 
Biomedical Informatics, Barcelona Biomedical Research 
Park, Barcelona, Spain) (68,69) according to the rank order 
(high to low) of scores for association with MI, hypertension, 
or cKd (Fig. 2). The network analysis revealed that the 13 
(Fig. 2A), 10 (Fig. 2B), and 11 (Fig. 2c) genes found to be 
Table V. 11 SNPs significantly (P<1.60x10-6) associated with hypertension in the exome-wide association study.
  Nucleotide Amino acid     P-value
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR (allele frequency)
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 0.54 1.30x10-7
PLCB2 rs200787930 c/T E1106K 15 40289298 1.2 0.55 3.33x10-7
COL6A3 rs146092501 c/T E1386K 2 237371861 1.2 0.55 3.50x10-7
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 0.56 3.52x10-7
MOB3C rs139537100 c/T R24Q 1 46615006 1.2 0.56 4.76x10-7
VPS33B rs199921354 c/T R80Q 15 91013841 1.2 0.55 4.84x10-7
NCR3 rs2515920 T/A  6 31594838 17.3 0.81 5.02x10-7
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 0.55 5.49x10-7
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 0.56 6.93x10-7
 rs769177 G/A  6 31579834 17.2 0.81 1.35x10-6
NFKBIL1 rs2071593 c/T  6 31545022 18.8 0.82 1.59x10-6
Allele frequencies were analyzed using Fisher's exact test. aMajor allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele 
frequency; OR, odds ratio.
Table VI. 11 SNPs significantly (P<1.59x10-6) associated with chronic kidney disease in the exome-wide association study.
  Nucleotide Amino acid     P-value
Gene SNP substitutiona substitution chromosome Position MAF (%) Allele OR (allele frequency)
COL6A5 rs200982668 G/A E2501K 3 130470894 1.3 0.21 5.08x10-9
MARCH1 rs61734696 G/T Q137K 4 164197303 1.2 0.22 1.97x10-8
MUC17 rs78010183 A/T T1305S 7 101035329 1.8 0.29 2.04x10-8
MOB3C rs139537100 c/T R24Q 1 46615006 1.2 0.23 4.91x10-8
PLCB2 rs200787930 c/T E1106K 15 40289298 1.2 0.23 4.94x10-8
CXCL8 rs188378669 G/T E31* 4 73741568 1.2 0.23 7.83x10-8
VPS33B rs199921354 c/T R80Q 15 91013841 1.2 0.23 7.86x10-8
TMOD4 rs115287176 G/A R277W 1 151170961 1.2 0.23 1.25x10-7
ADGRL3 rs192210727 G/T R580I 4 61909615 1.3 0.25 1.88x10-7
ZNF77 rs146879198 G/A R340* 19 2934109 1.2 0.24 2.95x10-7
COL6A3 rs146092501 c/T E1386K 2 237371861 1.2 0.24 2.99x10-7
Allele frequencies were analyzed using Fisher's exact test. aMajor allele/minor allele. SNP, single nucleotide polymorphism; MAF, minor allele 
frequency; OR, odds ratio.
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associated with MI, hypertension, and cKd, respectively, in 
the present study have potential direct or indirect interactions 
with the corresponding sets of 50 genes previously shown to 
be associated with these conditions.
Discussion
As the prevalence of cardiovascular and renal diseases 
is increasing and is therefore a key public health 
concern (1,20,31,32), the identification of genetic variants that 
confer susceptibility to MI, hypertension, and cKd is impor-
tant to prevent these conditions. In the present study, EWASs 
for MI, hypertension, and cKd were performed in subjects 
with early-onset forms of these conditions, with genetic factors 
likely to be more important in these individuals compared 
with those with late-onset forms.
In the MI study, it was found that 25 SNPs of 20 genes 
and two chromosomal loci were significantly associated with 
early-onset MI. Among these genes and loci, 6p21.3 (16), 
ATXN2 (9), BRAP (16), ACAD10 (9), ALDH2 (9), NAA25 (9), 
and HECTD4 (9) have previously been shown to be associ-
ated with MI or cAd. Therefore, 16 SNPs of 14 genes and 
one locus were newly identified. However, significant Ld 
was detected among three SNPs in ADGRL3, CXCL8, and 
MARCH1; between two SNPs in TCHP and GIT2; between 
two SNPs in CCDC63; and between two SNPs in PLCB2 
and VPS33B. Therefore, 11 novel loci (TMOD4, COL6A3, 
ADGRL3‑CXCL8‑MARCH1,  OR52E4,  TCHP‑GIT2, 
CCDC63, 12q24.1, OAS3, PLCB2‑VPS33B, GOSR2, ZNF77) 
were identified that confer susceptibility to MI.
In the hypertension study, 11 SNPs of 10 genes and 
one chromosomal locus were significantly associated with 
early-onset hypertension. None of these genes or loci have 
been found to be associated with systolic or diastolic BP or 
with hypertension in previous GWASs. However, there was 
significant LD between two SNPs in MOB3C and TMOD4; 
between two SNPs in CXCL8 and MARCH1; among three 
SNPs of NFKBIL1, 6p21.3, and NCR3; and between two 
SNPs in PLCB2 and VPS33B. Therefore six novel loci 
(MOB3C‑TMOD4, COL6A3, COL6A5, CXCL8‑MARCH1, 
NFKBIL1‑6p21.3‑NCR3, PLCB2‑VPS33B) were identified 
that confer susceptibility to hypertension.
In the CKD study, 11 SNPs in 11 genes were significantly 
associated with early-onset cKd. None of these genes have 
been shown to be associated with renal function-related 
traits or cKd in previous GWASs. However, there was 
significant LD between two SNPs in MOB3C and TMOD4; 
between two SNPs in PLCB2 and VPS33B; and among 
three SNPs in ADGRL3, CXCL8, and MARCH1. Therefore, 
seven new loci (MOB3C‑TMOD4, COL6A3, COL6A5, 
ADGRL3‑CXCL8‑MARCH1, MUC17, PLCB2‑VPS33B, 
ZNF77) were identified that confer susceptibility to CKD.
Table XI. Association between SNPs associated with hypertension and systolic or diastolic BP.
Gene SNP Systolic BP (mmHg) P-value diastolic BP (mmHg) P-value
MARCH1 rs61734696 G/T GG GT  <0.0001 GG GT  0.0239
   128±24 119±16   77±14 75±12  
PLCB2 rs200787930 c/T CC CT  <0.0001 CC CT  0.0482
   128±24 119±16   77±14 75±12  
COL6A3 rs146092501 c/T CC CT  <0.0001 CC CT  0.0584
   128±24 119±15   77±14 75±12  
COL6A5 rs200982668 G/A GG GA  <0.0001 GG GA  0.0341
   128±24 119±16   77±14 75±12  
MOB3C rs139537100 c/T CC CT  <0.0001 CC CT  0.0359
   128±24 119±16   77±14 75±12 
VPS33B rs199921354 c/T CC CT  <0.0001 CC CT  0.0348
   128±24 119±16   77±14 75±12 
NCR3 rs2515920 T/A TT TA AA <0.0001 TT TA AA 0.0062
   128±24 125±22 126±23  77±14 76±13 76±13
TMOD4 rs115287176 G/A GG GA  <0.0001 GG GA  0.0793
   128±24 119±16   77±14 75±12 
CXCL8 rs188378669 G/T GG GT  <0.0001 GG GT  0.0703
   128±24 119±16   77±14 75±12
 rs769177 G/A GG GA AA 0.0001 GG GA AA 0.0094
   128±24 125±22 126±23  77±14 76±13 76±13
NFKBIL1 rs2071593 c/T CC CT TT <0.0001 CC CT TT 0.0012
   128±24 125±22 127±23  77±14 76±13 76±13
data are presented as the mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based 
on Bonferroni's correction, P<0.0023 (0.05/22) was considered statistically significant and are shown in bold. SNP, single nucleotide 
polymorphism; BP, blood pressure.
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Furthermore, rs115287176 of TMOD4, rs146092501 of 
COL6A3, rs188378669 of CXCL8, rs61734696 of MARCH1, 
rs200787930 of PLCB2, and rs199921354 of VSP33B were 
significantly associated with all three diseases (MI, hyperten-
sion, and cKd); rs192210727 of ADGRL3 and rs146879198 
of ZNF77 were associated with both MI and cKd; and 
rs200982668 of COL6A5 and rs139537100 of MOB3C were 
associated with both hypertension and cKd. In addition, 
GOSR2, which was associated with MI, has previously been 
shown to be associated with systolic BP (23); and 6p21.3, 
which was associated with hypertension, has previously been 
shown to be associated with cAd (16). Therefore, 13 loci 
(MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, 
OR52E4,  TCHP‑ GIT2,  CCDC63,  12q24.1,  OAS3, 
PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, 
MUC17) were newly identified that confer susceptibility to 
MI, hypertension, or cKd. Genes, chromosomal loci, and 
SNPs identified in the present study, in particular, those 
significantly associated with two or three diseases, may prove 
to be informative for clinical practice.
In the MI study, associations of CXCL8 to plasma total 
cholesterol (70), of MARCH1 to serum adiponectin concentra-
tion (71), of 12q24.1 and OAS3 to plasma HdL-cholesterol (72), 
of PLCB2 to plasma triglycerides (70), of VPS33B to type 2 
diabetes mellitus (73), and of GOSR2 to systolic BP (23) have 
been shown in previous GWASs. In the present study, eight loci 
(TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, OR52E4, 
CCDC63, 12q24.1, PLCB2‑VPS33B, ZNF77) newly associ-
ated with MI were significantly associated with one or more 
intermediate phenotypes; in particular, five loci (TMOD4, 
Table XII. Association between SNPs associated with chronic kidney disease and the serum concentration of creatinine and 
eGFR.
Gene SNP Serum creatinine (µmol/l) P-value eGFR (ml min-1 1.73 m-2) P-value
COL6A5 rs200982668 G/A GG GA  0.0281 GG GA  <0.0001
   93.6±138.5 61.8±34.4   79.3±32.9 95.2±20.2  
MARCH1 rs61734696 G/T GG GT  0.0352 GG GT  <0.0001
   93.5±138.3 62.4±35.0   79.3±32.9 94.7±20.3  
MUC17 rs78010183 A/T AA AT  0.0068 AA AT  <0.0001
   93.8±139.0 59.2±18.8   79.4±33.0 93.0±19.9  
MOB3C rs139537100 c/T CC CT  0.0374 CC CT  <0.0001
   93.5±138.4 62.4±35.5   79.3±32.9 94.9±20.8  
PLCB2 rs200787930 c/T CC CT  0.0380 CC CT  <0.0001
   93.5±138.3 62.5±35.4   79.3±32.9 94.8±20.8  
CXCL8 rs188378669 G/T GG GT  0.0397 GG GT  <0.0001
   93.5±138.3 62.6±35.6   79.3±32.9 95.0±20.9  
VPS33B rs199921354 c/T CC CT  0.0406 CC CT  <0.0001
   93.5±138.4 62.6±35.8   79.3±32.9 94.8±21.1  
TMOD4 rs115287176 G/A GG GA  0.0426 GG GA  <0.0001
   93.4±138.2 62.8±35.8   79.4±32.9 94.6±20.9  
ADGRL3 rs192210727 G/T GG GT TT 0.1294 GG GT TT 0.0002
   93.2±137.5 63.0±35.8 64.5  79.3±32.9 94.4±21.4 94.3 
ZNF77 rs146879198 G/A GG GA  0.0491 GG GA  <0.0001
   93.4±138.1 63.1±36.4   79.4±32.9 94.3±21.1  
COL6A3 rs146092501 c/T CC CT  0.0466 CC CT  <0.0001
   93.4±138.2 62.8±36.4   79.4±32.9 94.6±21.2  
data are presented as the mean ± standard deviation and were compared among genotypes by one-way analysis of variance. Based 
on Bonferroni's correction, P<0.0023 (0.05/22) was considered statistically significant and are shown in bold. SNP, single nucleotide 
polymorphism; eGFR, estimated glomerular filtration rate.
Figure 1. Ld map of 13 SNPs at 12q24.11-12q24.13 associated with 
myocardial infarction. Ld was calculated as the square of the correlation 
coefficient (r2), with the extent of Ld increasing according to the color order 
of blue < gray < red. LD, linkage disequilibrium.
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Figure 2. (A) Network analysis of the 13 genes (TMOD4, COL6A3, ADGRL3, CXCL8, MARCH1, OR52E4, TCHP, GIT2, CCDC63, OAS3, PLCB2, VPS33B, 
ZNF77) associated with MI in the present study (red circles) was performed to predict functional gene-gene interactions with the use of the GeneMANIA 
cytoscape plugin (http://apps.cytoscape.org/apps/genemania) and cytoscape v3.4.0 software (http://www.cytoscape.org). A total of 50 genes (green circles) 
selected from the disGeNET database (http://www.disgenet.org/web/disGeNET) according to the rank order (high to low) of scores for association with MI 
were applied to the analysis. Interactions between red circles or between red and green circles are indicated by bold lines. Molecules represented by gray 
circles are putative mediators of interactions between genes. (B) Network analysis of the 10 genes (MOB3C, TMOD4, COL6A3, COL6A5, CXCL8, MARCH1, 
NFKBIL1, NCR3, PLCB2, VPS33B) associated with hypertension in the present study (red circles) was performed in the same manner; 50 genes (green circles) 
selected from the disGeNET database according to the rank order of scores for association with hypertension were applied to the analysis. MI, myocardial 
infarction.
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COL6A3, ADGRL3‑CXCL8‑MARCH1, PLCB2‑VPS33B, 
ZNF77) associated with two or three diseases were associ-
ated with three or four intermediate phenotypes. As these 
intermediate phenotypes are important risk factors for MI, 
the association between these loci and MI may be attributable, 
at least in part, to their effects on intermediate phenotypes. 
By contrast, three loci (TCHP‑GIT2, OAS3, and GOSR2) 
associated with MI were not associated with intermediate 
phenotypes. The molecular mechanisms underlying the asso-
ciation between these loci and MI remain to be elucidated.
In the hypertension study, although the six loci 
(MOB3C‑TMOD4, COL6A3, COL6A5, CXCL8‑MARCH1, 
NFKBIL1‑6p21.3‑NCR3, PLCB2‑VPS33B) identified in the 
present study were all significantly associated with systolic BP, 
they have not been shown to be associated with BP or hyper-
tension by previous GWASs. The associations of NFKBIL1 
and NCR3 to plasma total cholesterol (74), of 6p21.3 to plasma 
total cholesterol and triglycerides (74), and of CXCL8 (70), 
MARCH1 (71), PLCB2 (70), and VPS33B (73) to lipid or 
glucose metabolism have been shown in previous GWASs. The 
effects of these loci on lipid or glucose metabolism may influ-
ence BP or hypertension, although the functional relevance of 
these loci to the pathogenesis of hypertension remains to be 
fully elucidated.
In the cKd study, although the seven loci (MOB3C‑TMOD4, 
COL6A3, COL6A5, ADGRL3‑CXCL8‑MARCH1, MUC17, 
PLCB2‑VPS33B, ZNF77) identified in the present study were 
all significantly associated with eGFR, they have not been 
shown to be associated with renal function-related traits or 
cKd in previous GWASs. The associations of CXCL8 (70), 
MARCH1 (71), PLCB2 (70), and VPS33B (73) to lipid or 
glucose metabolism have been demonstrated in previous 
GWASs. The effects of these loci on lipid or glucose metabo-
lism may contribute, at least in part, to renal function or the 
development of cKd, although the molecular mechanisms 
underlying the association between these loci and cKd remain 
to be elucidated.
Previous GWASs have identified potential biological 
pathways underlying the associations between genetic loci 
and cAd (75,76). Network analysis of functional gene-gene 
interactions may be informative with regard to the clarification 
of biological processes underlying CAD and to the identifica-
tion of therapeutic targets for this condition (77). Therefore the 
present study performed GO and network analyses to predict 
biological processes associated with the identified genes, and 
the interactions between these genes and those previously 
shown to be associated with MI, hypertension, or cKd.
GO analysis of the 13 genes associated with MI suggested 
that the functions of TMOD4 (actin filament organization); 
COL6A3 (cell adhesion and extracellular matrix organiza-
tion); ADGRL3, OR52E4, and PLCB2 (G protein-coupled 
receptor signaling); CXCL8 (angiogenesis and inflammatory 
response); MARCH1 and OAS3 (immune response); TCHP 
(apoptotic process); GIT2 (regulation of GTPase activity); and 
VPS33B (vesicle-mediated transport and platelet α-granule 
organization) may be associated with the pathogenesis 
Figure 2. continued. (c) Network analysis of the 11 genes (MOB3C, TMOD4, COL6A3, COL6A5, ADGRL3, CXCL8, MARCH1, MUC17, PLCB2, VPS33B, 
ZNF77) associated with cKd in the present study (red circles) was performed in the same manner; 50 genes (green circles) selected from the disGeNET 
database according to the rank order of scores for association with cKd were applied to the analysis. cKd, chronic kidney disease.
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of MI. For the 10 genes associated with hypertension, the 
functions of TMOD4, COL6A3, COL6A5 (cell adhesion), 
CXCL8, MARCH1, NFKBIL1 (NF-κB signaling), NCR3 
(immune response), PLCB2, and VPS33B may be associated 
with the pathogenesis of hypertension. Among the 11 genes 
associated with cKd, the functions of COL6A3, COL6A5, 
ADGRL3, CXCL8, MARCH1, MUC17 (cellular homeostasis), 
PLCB2, and VPS33B may be associated with the pathogen-
esis of cKd. Network analysis showed that the 13, 10, and 
11 genes found to be associated with MI, hypertension, and 
cKd, respectively, in the present study had direct or indirect 
interactions with the corresponding sets of 50 genes selected 
from the disGeNET database (68,69). However, the under-
lying molecular mechanisms of these interactions remain to 
be elucidated.
In our previous studies, it was shown that nine, nine, and 
four SNPs were associated with MI (P<0.01), hypertension 
(P<0.01), and CKD (P<0.05), respectively, as determined by 
multivariable logistic regression analysis with adjustment 
for covariates following an initial EWAS screening of allele 
frequencies among subjects with early-onset and late-onset 
forms of these conditions (50-52). The associations between 
five of the nine SNPs [rs202103723 (P=0.0107), rs188212047 
(P=0.0039), rs1265110 (P=0.0004), rs9258102 (P=0.0373), 
rs439121 (P=0.0063)] and MI were replicated (P<0.05) in the 
present study. The associations between six of the nine SNPs 
[rs150854849 (P=0.0123), rs2867125 (P=0.0111), rs202069030 
(P=6.40x10-10), rs139012426 (P=5.50x10-6), rs12229654 
(P=0.0003), rs201633733 (P=0.0356)] and hypertension were 
replicated (P<0.05) in the present study. By contrast, none 
of the associations between the four SNPs and cKd were 
replicated in the present study, indicative of the importance 
of age in the development of cKd. These results suggested 
that genetic variants associated with MI, hypertension, and 
cKd differ, in part, between individuals with early-onset and 
late-onset disease.
There were several limitations to the present study: i) As 
that the results were not replicated, their validation is necessary 
Table XIII. Association between genes, chromosomal loci, and SNPs associated with MI in the present study and previously 
examined cardiovascular disease-related phenotypes.
Gene/chr. locus SNP chr. Position Previously examined phenotypes
TMOD4 rs115287176 1 151170961 None
COL6A3 rs146092501 2 237371861 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
6p21.3 rs2596548 6 31362769 MI (21971053)
 rs2523644  31374707 
OR52E4 rs11823828 11 5884973 None
TCHP rs74416240 12 109904793 None
GIT2 rs925368 12 109953174 None
CCDC63 rs10849915 12 110895818 None
 rs10774610  110902439 
12q24.1 rs12229654 12 110976657 HdL-cholesterol (21909109)
ATXN2 rs7969300 12 111555908 MI (19820697, 19198610), cAd (19820697, 23202125, 21060863)
BRAP rs3782886 12 111672685 MI (21971053, 19820697, 21107343), cAd (21971053, 21572416,
    23202125, 19820697, 23364394, 21060863)
ACAD10 rs11066015 12 111730205 cAd (23364394, 23202125)
ALDH2 rs671 12 111803962 MI (21971053), cAd (21971053, 21572416, 23202125) 
NAA25 rs12231744 12 112039251 MI (19820697, 23202125), cAd (21971053, 19820697)
HECTD4 rs2074356 12 112207597 MI (19820697), cAd (21971053, 21572416, 22751097, 19820697, 
    23364394, 23202125)
 rs11066280  112379979
OAS3 rs2072134 12 112971371 HdL-cholesterol (21909109)
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
GOSR2 rs1052586 17 46941097 Systolic BP (21909110, 21909115)
ZNF77 rs146879198 19 2934109 None
data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (https://grasp.nhlbi.
nih.gov/Search.aspx) with P<1.0x10-6. Numbers in parentheses are PubMed Ids. SNP, single nucleotide polymorphism; MI, myocardial infarc-
tion; chr., chromosome; HdL, high density lipoprotein; cAd, coronary artery disease; BP, blood pressure.
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in independent study populations or in other ethnicities; ii) it 
is possible that SNPs identified in the present study are in LD 
with other genetic variants in the same gene or in other nearby 
genes that are actually responsible for the development of MI, 
hypertension, or cKd; iii) the functional relevance of identi-
fied SNPs to the pathogenesis of MI, hypertension, and CKD 
remains to be elucidated. due to the lack of experiments for 
functional analyses, the association of the SNPs identified in 
the present study with MI, hypertension, and cKd requires 
careful interpretation.
In conclusion, the present study identified 13 loci 
(MOB3C‑TMOD4, COL6A3, ADGRL3‑CXCL8‑MARCH1, 
OR52E4,  TCHP‑ GIT2,  CCDC63,  12q24.1,  OAS3, 
PLCB2‑VPS33B, ZNF77, COL6A5, NFKBIL1‑NCR3, 
MUC17) that confer susceptibility to MI, hypertension, or 
cKd. determination of the genotypes for the SNPs at these 
loci may provide informative for assessment of the genetic risk 
for MI, hypertension, and cKd.
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Table XIV. Association between genes, chromosomal loci, and SNPs associated with hypertension in the present study and 
previously examined cardiovascular disease-related phenotypes.
Gene/chr. locus SNP chr. Position Previously examined phenotypes
MOB3C rs139537100 1 46615006 None
TMOD4 rs115287176 1 151170961 None
COL6A3 rs146092501 2 237371861 None
COL6A5 rs200982668 3 130470894 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
NFKBIL1 rs2071593 6 31545022 Total cholesterol (20686565)
6p21.3 rs769177 6 31579834 Total cholesterol (20686565), triglycerides (20686565), cAd (21971053)
NCR3 rs2515920 6 31594838 Total cholesterol (20686565)
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (https://grasp.nhlbi.
nih.gov/Search.aspx) with a P<1.0x10-6. Numbers in parentheses are PubMed Ids. SNP, single nucleotide polymorphism; chr., chromosome; 
cAd, coronary artery disease.
Table XV. Association between genes and SNPs associated with chronic kidney disease in the present study and previously 
examined cardiovascular and renal phenotypes.
Gene SNP chr. Position Previously examined phenotypes
MOB3C rs139537100 1 46615006 None
TMOD4 rs115287176 1 151170961 None
COL6A3 rs146092501 2 237371861 None
COL6A5 rs200982668 3 130470894 None
ADGRL3 rs192210727 4 61909615 None
CXCL8 rs188378669 4 73741568 Total cholesterol (23063622)
MARCH1 rs61734696 4 164197303 Adiponectin concentrations (20887962)
MUC17 rs78010183 7 101035329 None
PLCB2 rs200787930 15 40289298 Triglycerides (23063622)
VPS33B rs199921354 15 91013841 Type 2 diabetes (22885922)
ZNF77 rs146879198 19 2934109 None
data were obtained from the Genome-Wide Repository of Associations Between SNPs and Phenotypes Search database (https://grasp.nhlbi.
nih.gov/Search.aspx) with a P<1.0x10-6. Numbers in parentheses are PubMed Ids. SNP, single nucleotide polymorphism; chr., chromosome.
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